Last reviewed · How we verify
Topotecan - usual
At a glance
| Generic name | Topotecan - usual |
|---|---|
| Also known as | Usual Topotecan Capsule Chemotherapy |
| Sponsor | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma (PHASE3)
- Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms (PHASE2, PHASE3)
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer (PHASE1)
- Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |